Endothelial progenitor cells: a promising therapeutic alternative for cardiovascular disease.
The integrity and functional activity of the endothelial monolayer play a critical role in preventing atherosclerotic disease progression. Endothelial cell (EC) damage by atherosclerosis risk factors can result in EC apoptosis with loss of the integrity of the endothelium. Thus, approaches to repair the injured vessels with the goal of regenerating ECs have been tested in preclinical experimental models and in clinical studies. Indeed, endothelial progenitor cells (EPCs) originating from the bone marrow have been shown to incorporate into sites of neovascularization and home to sites of endothelial denudation. These cells may provide an endogenous repair mechanism to counteract ongoing risk factor-induced endothelial injury and to replace dysfunctional endothelium. Risk factors for coronary artery disease, such as age, smoking, hypertension, hyperlipidemia, and diabetes, however, reduce the number and functional activity of circulating EPCs, potentially restricting the therapeutic prospective of progenitor cells and limiting the regenerative capacity. Furthermore, the impairment of EPCs by risk factors may contribute to atherogenesis and atherosclerotic disease progression. The article reviews the role of EPCs in atherogenesis and in predicting cardiovascular outcomes, and highlights the potential challenges in developing therapeutic strategies aiming to interfere with the balance of injury and repair mechanisms.
Dong
Chunming
C
Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Goldschmidt-Clermont
Pascal J
PJ
D053687:Adult Stem Cells; D001854:Bone Marrow Cells; D002318:Cardiovascular Diseases / Q000503:physiopathology / Q000628:therapy*; D064987:Cell- and Tissue-Based Therapy; D004730:Endothelium, Vascular; D006801:Humans; D012196:Review Literature as Topic; D033581:Stem Cell Transplantation; D013234:Stem Cells